Continuous and early prediction of future moderate and severe Acute Kidney Injury in critically ill patients: Development and multi-centric, multi-national external validation of a machine-learning model.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2023
Historique:
received: 14 12 2022
accepted: 05 06 2023
medline: 27 7 2023
pubmed: 25 7 2023
entrez: 25 7 2023
Statut: epublish

Résumé

Acute Kidney Injury (AKI) is a major complication in patients admitted to Intensive Care Units (ICU), causing both clinical and economic burden on the healthcare system. This study develops a novel machine-learning (ML) model to predict, with several hours in advance, the AKI episodes of stage 2 and 3 (according to KDIGO definition) acquired in ICU. A total of 16'760 ICU adult patients from 145 different ICU centers and 3 different countries (US, Netherland, Italy) are retrospectively enrolled for the study. Every hour the model continuously analyzes the routinely-collected clinical data to generate a new probability of developing AKI stage 2 and 3, according to KDIGO definition, during the ICU stay. The predictive model obtains an auROC of 0.884 for AKI (stage 2/3 KDIGO) prediction, when evaluated on the internal test set composed by 1'749 ICU stays from US and EU centers. When externally tested on a multi-centric US dataset of 6'985 ICU stays and multi-centric Italian dataset of 1'025 ICU stays, the model achieves an auROC of 0.877 and of 0.911, respectively. In all datasets, the time between model prediction and AKI (stage 2/3 KDIGO) onset is at least of 14 hours after the first day of ICU hospitalization. In this study, a novel ML model for continuous and early AKI (stage 2/3 KDIGO) prediction is successfully developed, leveraging only routinely-available data. It continuously predicts AKI episodes during ICU stay, at least 14 hours in advance when the AKI episode happens after the first 24 hours of ICU admission. Its performances are validated in an extensive, multi-national and multi-centric cohort of ICU adult patients. This ML model overcomes the main limitations of currently available predictive models. The benefits of its real-world implementation enable an early proactive clinical management and the prevention of AKI episodes in ICU patients. Furthermore, the software could be directly integrated with IT system of the ICU.

Sections du résumé

BACKGROUND
Acute Kidney Injury (AKI) is a major complication in patients admitted to Intensive Care Units (ICU), causing both clinical and economic burden on the healthcare system. This study develops a novel machine-learning (ML) model to predict, with several hours in advance, the AKI episodes of stage 2 and 3 (according to KDIGO definition) acquired in ICU.
METHODS
A total of 16'760 ICU adult patients from 145 different ICU centers and 3 different countries (US, Netherland, Italy) are retrospectively enrolled for the study. Every hour the model continuously analyzes the routinely-collected clinical data to generate a new probability of developing AKI stage 2 and 3, according to KDIGO definition, during the ICU stay.
RESULTS
The predictive model obtains an auROC of 0.884 for AKI (stage 2/3 KDIGO) prediction, when evaluated on the internal test set composed by 1'749 ICU stays from US and EU centers. When externally tested on a multi-centric US dataset of 6'985 ICU stays and multi-centric Italian dataset of 1'025 ICU stays, the model achieves an auROC of 0.877 and of 0.911, respectively. In all datasets, the time between model prediction and AKI (stage 2/3 KDIGO) onset is at least of 14 hours after the first day of ICU hospitalization.
CONCLUSIONS
In this study, a novel ML model for continuous and early AKI (stage 2/3 KDIGO) prediction is successfully developed, leveraging only routinely-available data. It continuously predicts AKI episodes during ICU stay, at least 14 hours in advance when the AKI episode happens after the first 24 hours of ICU admission. Its performances are validated in an extensive, multi-national and multi-centric cohort of ICU adult patients. This ML model overcomes the main limitations of currently available predictive models. The benefits of its real-world implementation enable an early proactive clinical management and the prevention of AKI episodes in ICU patients. Furthermore, the software could be directly integrated with IT system of the ICU.

Identifiants

pubmed: 37490482
doi: 10.1371/journal.pone.0287398
pii: PONE-D-22-34232
pmc: PMC10368244
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0287398

Informations de copyright

Copyright: © 2023 Alfieri et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

Valentina Cauda and Andrea Ancona hold the international patent WO2020157557 entitled “A monitoring and prediction system of diuresis for the calculation of kidney failure risk, and the method thereof”. All the other authors declare no conflict of interest.

Références

Medicine (Baltimore). 2016 May;95(19):e3674
pubmed: 27175701
Heart Vessels. 2021 Mar;36(3):330-336
pubmed: 33034713
Nephrol Dial Transplant. 2022 Jan 25;37(2):271-284
pubmed: 34661677
Crit Care. 2011;15(3):R135
pubmed: 21645384
J Am Soc Nephrol. 2020 Sep;31(9):2145-2157
pubmed: 32669322
PLoS One. 2021 May 25;16(5):e0251048
pubmed: 34033655
Crit Care. 2016 Mar 15;20:69
pubmed: 26983854
Lancet. 2015 Jun 27;385(9987):2616-43
pubmed: 25777661
Nephrol Dial Transplant. 2016 Nov;31(11):1846-1854
pubmed: 27190331
Intensive Care Med. 2017 Jun;43(6):764-773
pubmed: 28130688
Scand J Trauma Resusc Emerg Med. 2017 Feb 10;25(1):11
pubmed: 28187736
J Am Soc Nephrol. 2015 Sep;26(9):2231-8
pubmed: 25568178
BMJ. 2021 Jan 18;372:m4786
pubmed: 33461986
J Nephrol. 2021 Dec;34(6):1875-1886
pubmed: 33900581
Kidney Int. 2022 Jun;101(6):1271-1281
pubmed: 35398477
Physiol Meas. 2018 Aug 31;39(8):084004
pubmed: 29972378
J Nephrol. 2022 Nov;35(8):2047-2056
pubmed: 35554875
PLoS One. 2019 Nov 14;14(11):e0224655
pubmed: 31725746
BMJ Open. 2022 Mar 03;12(3):e054092
pubmed: 35241466
Ren Fail. 2009;31(10):884-90
pubmed: 20030522
Nephrol Dial Transplant. 2017 Feb 1;32(2):265-272
pubmed: 28088774
Crit Care Med. 2021 Jun 1;49(6):e563-e577
pubmed: 33625129
Sci Data. 2018 Sep 11;5:180178
pubmed: 30204154
Acta Physiol (Oxf). 2017 Mar;219(3):554-572
pubmed: 27474473
J Am Soc Nephrol. 2021 Jan;32(1):151-160
pubmed: 32883700
Front Physiol. 2022 Aug 24;13:960059
pubmed: 36091391
Adv Chronic Kidney Dis. 2021 Jan;28(1):74-82
pubmed: 34389139
Nat Rev Nephrol. 2018 Oct;14(10):607-625
pubmed: 30135570
Kidney Int. 2015 Jan;87(1):62-73
pubmed: 25317932
Fed Pract. 2021 Nov;38(11):508-515b
pubmed: 35136335
Ann Intensive Care. 2019 Aug 6;9(1):87
pubmed: 31388845
Kidney Int. 2010 Mar;77(6):536-42
pubmed: 20042998
Intensive Care Med. 1996 Dec;22(12):1368-78
pubmed: 8986488
BMC Nephrol. 2017 Feb 20;18(1):70
pubmed: 28219327
J Am Soc Nephrol. 2009 Jun;20(6):1217-21
pubmed: 19389851
Kidney Int. 2011 Oct;80(7):760-7
pubmed: 21716258
Nat Med. 2020 Mar;26(3):364-373
pubmed: 32152583
BMC Bioinformatics. 2009 Jul 10;10:213
pubmed: 19591666
Pract Lab Med. 2022 Apr 02;30:e00270
pubmed: 35465620
Kidney Int. 2019 Jan;95(1):21-23
pubmed: 30606416
PLoS One. 2017 Jul 19;12(7):e0180750
pubmed: 28723973
Clin J Am Soc Nephrol. 2014 Jun 6;9(6):1007-14
pubmed: 24677557
J Am Soc Nephrol. 2013 Jan;24(1):37-42
pubmed: 23222124
Kidney360. 2021 Nov 18;3(2):376-381
pubmed: 35373136
Am J Kidney Dis. 2007 Nov;50(5):712-20
pubmed: 17954284
Sci Data. 2016 May 24;3:160035
pubmed: 27219127
Eur J Cardiothorac Surg. 2022 Oct 4;62(5):
pubmed: 35521994
Sci Rep. 2018 Apr 17;8(1):6085
pubmed: 29666385
Nature. 2019 Aug;572(7767):116-119
pubmed: 31367026
Crit Care. 2022 Nov 12;26(1):349
pubmed: 36371256
Int J Clin Pract. 2016 Apr;70(4):330-9
pubmed: 26799821
PLoS One. 2018 Aug 8;13(8):e0200584
pubmed: 30089118
Int Urol Nephrol. 2017 Feb;49(2):295-302
pubmed: 27817055
Nephrol Dial Transplant. 2010 Dec;25(12):3911-8
pubmed: 20100732

Auteurs

Francesca Alfieri (F)

U-Care Medical srl, Torino, Italy.

Andrea Ancona (A)

U-Care Medical srl, Torino, Italy.

Giovanni Tripepi (G)

CNR-IFC, Clinical Epidemiology and Pathophysiology of Renal Diseases and Hypertension, Reggio Calabria, Italy.

Andrea Rubeis (A)

Department of Applied Science and Technology, Politecnico di Torino, Turin, Italy.

Niccolò Arjoldi (N)

Department of Applied Science and Technology, Politecnico di Torino, Turin, Italy.

Stefano Finazzi (S)

Dipartimento di Salute Pubblica, Laboratorio di Clinical Data Science, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Ranica, Bergamo, Italy.

Valentina Cauda (V)

U-Care Medical srl, Torino, Italy.
Department of Applied Science and Technology, Politecnico di Torino, Turin, Italy.

Riccardo Maria Fagugli (RM)

S.C. Nefrologia e Dialisi, Azienda Ospedaliera di Terni, Terni, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH